A Phase 2, multi-center, randomized, double-blind, placebo-controlled, 12-week study to evaluate the efficacy and safety of olorinab in IBS patients experiencing abdominal pain


Patients may be able to take part in the clinical program if they*:

  • Are 18-70 years of age
  • Have been diagnosed with IBS with constipation or diarrhea (IBS-C or IBS-D)
  • Experience abdominal pain due to IBS
*Other eligibility criteria apply

For more information please visit www.MyIBSPainStudy.com